论文部分内容阅读
目的探讨联合检测抗核抗体(ANA)、抗可提取性抗原抗体(抗ENA)及抗双链DNA抗体的临床价值。方法采用间接免疫荧光检测ANA,采用胶体金斑点渗透法检测抗ds-DNA抗体,谱采用免疫印迹法检测抗ENA、抗Sm、抗nRNP/Sm、抗SS-A、抗SS-B、抗Scl-70、抗Jo-1。结果 SLE组ANA阳性率为70.8%,抗ds-DNA抗体阳性率为47.5%,抗Sm抗体阳性率为37.5%,抗nRNP/Sm抗体阳性率为29.16%,抗SS-A抗体阳性率为26.66%,抗SS-B抗体阳性率为21.66%,抗Scl-70抗体阳性率为1.66%,抗Jo-1抗体阳性率为0%,对照组中只有ANA的阳性率为6.67%,其他抗体均为阴性用间接免疫荧光法检测ANA核颗粒型、核均质型、浆颗粒型、核仁型、着丝点型分别为62.4%、23.5%,10.6%,2.4%,1.2%。结论 ANA、抗ds-DNA抗体和抗Sm抗体可作为检测的标志性抗体,联合检测可提高检测率,对病情的诊断治疗、追踪和预后判定均有重要价值。
Objective To explore the clinical value of combined detection of anti-nuclear antibody (ANA), anti-extractable antigen antibody (anti-ENA) and anti-double-stranded DNA antibody. Methods ANA was detected by indirect immunofluorescence. The anti-dsDNA antibody was detected by gold staining of colloidal gold spot. The anti-Smn, anti-nRNP / Sm, anti-SSR, anti- -70, anti-Jo-1. Results The ANA positive rate was 70.8%, anti-dsDNA antibody positive rate was 47.5%, anti-Sm antibody positive rate was 37.5%, anti-nRNP / Sm antibody positive rate was 29.16%, anti-SS-A antibody positive rate was 26.66 %, The positive rate of anti-SS-B antibody was 21.66%, the positive rate of anti-Scl-70 antibody was 1.66%, the positive rate of anti-Jo-1 antibody was 0%, the positive rate of ANA in control group was 6.67% Negative ANA nuclear particle type, nuclear homogenate, plasma particle type, nucleolus type, and centromere type were 62.4%, 23.5%, 10.6%, 2.4% and 1.2% respectively by indirect immunofluorescence assay. Conclusion ANA, anti-dsDNA antibody and anti-Sm antibody can be used as the detection of the antibody, combined detection can improve the detection rate of diagnosis and treatment of disease, tracking and prognosis of great value.